Cetuximab

Cetuximab is a recombinant chimeric IgG1 monoclonal antibody and an epidermal growth factor receptor (EGFR) antagonist used in the treatment of selected cancers. It binds to EGFR, a cell-surface receptor involved in signalling pathways that regulate tumour-cell growth, proliferation, survival, and spread. By blocking EGFR signalling, cetuximab can interfere with growth-promoting signals in EGFR-expressing tumour cells. It is administered by intravenous infusion rather than by mouth. Current approved uses include certain squamous cell carcinomas of the head and neck and selected metastatic colorectal cancers. In colorectal cancer, treatment selection depends on molecular characteristics such as RAS status and, for a specific indication, BRAF V600E mutation status. Cetuximab may be used alone or alongside chemotherapy, radiotherapy, or another targeted medicine depending on the indication and regulatory jurisdiction. Because it is a biologic anticancer medicine, administration requires clinical supervision, premedication to reduce infusion-reaction risk, and monitoring for potentially serious adverse effects.

Cetuximab was developed as a chimeric mouse-human monoclonal antibody directed against EGFR. The United States FDA granted its original biologics approval on February 12, 2004, for EGFR-expressing metastatic colorectal cancer in specified treatment settings. The European Commission granted EU-wide marketing authorisation for Erbitux on June 29, 2004. Subsequent regulatory expansions established its role in squamous cell carcinoma of the head and neck and refined colorectal-cancer use according to tumour biomarkers. FDA records document later colorectal-cancer indications involving KRAS wild-type disease and BRAF V600E mutation-positive metastatic colorectal cancer, while the EMA authorises additional biomarker-defined colorectal-cancer combinations, including certain first-line BRAF V600E-positive disease settings. Major clinical development programs included studies of cetuximab with radiotherapy in locally advanced head and neck cancer, the EXTREME program in recurrent or metastatic head and neck cancer, and the CRYSTAL program evaluating cetuximab with chemotherapy in metastatic colorectal cancer.

Cetuximab is approved for selected patients with squamous cell carcinoma of the head and neck, including locally or regionally advanced disease treated with radiation therapy and recurrent or metastatic disease treated with platinum-based chemotherapy plus fluorouracil; U.S. labeling also includes single-agent treatment after failure of platinum-based therapy. In metastatic colorectal cancer, U.S. labeling covers EGFR-expressing, KRAS wild-type disease in combination with FOLFIRI for first-line treatment, with irinotecan after failure of irinotecan-based chemotherapy, or as monotherapy after failure or intolerance of oxaliplatin- and irinotecan-based therapy. U.S. labeling also includes cetuximab with encorafenib for adults with BRAF V600E mutation-positive metastatic colorectal cancer after prior therapy. EMA-approved indications additionally include specified RAS wild-type metastatic colorectal cancer regimens and, in its product information, BRAF V600E-positive metastatic colorectal cancer combinations involving encorafenib and FOLFOX in defined treatment settings. Biomarker testing is therefore important when cetuximab is being considered for colorectal cancer.

Cetuximab is administered by intravenous infusion under supervision, with an H1-receptor antagonist given before treatment to reduce the risk of infusion reactions. For treatment with chemotherapy or as monotherapy, the U.S. regimen may be given weekly, beginning with 400 mg/m² followed by 250 mg/m² weekly, or every two weeks at 500 mg/m². When combined with radiation therapy for head and neck cancer, the initial dose is 400 mg/m² given one week before radiotherapy, followed by 250 mg/m² weekly during the radiation course, generally for 6–7 weeks. The infusion is completed at least one hour before chemotherapy or radiotherapy when required by the regimen. Treatment is generally continued until disease progression or unacceptable toxicity; treatment schedules and combinations can vary by indication and regulatory jurisdiction.

Common adverse effects include skin reactions such as acne-like rash, dry or itchy skin and nail changes, as well as diarrhea, headache and infections. Fatigue, nausea, abdominal symptoms, decreased appetite, arthralgia and rash may also occur, particularly when cetuximab is combined with encorafenib. Skin toxicity is a characteristic effect of EGFR inhibition and can range from mild irritation to clinically significant dermatologic complications. The frequency and severity of adverse effects vary according to the cancer being treated and the other medicines or radiation used with cetuximab.

Important risks include serious and potentially fatal infusion reactions, cardiopulmonary arrest or sudden death reported in certain head and neck cancer treatment settings, pulmonary toxicity including possible interstitial lung disease, severe dermatologic toxicity and clinically important electrolyte abnormalities, particularly hypomagnesemia with associated potassium or calcium abnormalities. Cetuximab should be interrupted or permanently discontinued according to the severity and recurrence of certain adverse reactions, and serious infusion reactions require permanent discontinuation under U.S. labeling. Serum magnesium, potassium and calcium should be monitored during treatment and for at least eight weeks after treatment. Cetuximab is also associated with embryo-fetal toxicity, so pregnancy risks and appropriate contraception should be addressed before and during treatment. In metastatic colorectal cancer, cetuximab should not be used for RAS-mutant disease or when the relevant RAS mutation status is unknown under U.S. labeling.

Before treatment, clinicians should confirm the cancer indication and, where required, appropriate tumour biomarker results such as RAS or BRAF V600E status. Baseline assessment commonly includes clinical evaluation, blood counts and chemistry testing with particular attention to magnesium, potassium and calcium, together with assessment of pulmonary and dermatologic status when clinically appropriate. Patients should be monitored during and after infusion because severe reactions can occur. Sun exposure may worsen some dermatologic effects, and patients receiving cetuximab should receive appropriate skin-care counselling. Pregnancy should be avoided during treatment because of potential fetal harm, and U.S. prescribing information advises against breastfeeding during treatment. Classic CYP-mediated drug interactions are generally not the central interaction concern with this monoclonal antibody; however, interactions and additive toxicities with chemotherapy, radiotherapy, encorafenib and other cancer treatments must be considered as part of the complete regimen.

Confirm the indication and required biomarker results before initiating treatment, particularly for metastatic colorectal cancer. Review baseline electrolytes and establish a plan for repeated magnesium, potassium and calcium monitoring during treatment and after completion. Ensure appropriate premedication and an adequately equipped setting for intravenous administration, with observation for infusion reactions. Counsel patients to report new rash, severe skin changes, nail inflammation, respiratory symptoms, fever, weakness or symptoms that could indicate electrolyte abnormalities. For patients receiving concurrent chemotherapy or radiotherapy, coordinate administration timing and toxicity monitoring across the oncology team. Dose interruption or reduction should follow the applicable prescribing information when significant dermatologic, pulmonary or infusion-related toxicity develops.